arq part ii data management

ARQ part II data management

Training pack 3: Practical issues and

detailed guidance notes

The completion process

• Set up an ARQ team• Make a work plan for the

search for, collection and retrieval of potential data sources and the consultation of experts

• Assign tasks and “sub-tasks”• Determine procedures for

decision-making • Prepare draft versions of the

ARQ for discussion• Submit final version of ARQ• Evaluate completion process

Submission

• Timely submission is crucial• If tasks require more time than

the submission date permits:– Implement for the following year’s

ARQ with an extended schedule

• If the data requested are not yet available: – Propose short-, mid- and long-term

actions to remedy the omissions– Ask for UNODC assistance and

advice for implementation when needed

Form fields

• Acrobat format form– Some text fields only accept numbers– Size of text fields restricts amount of text

• Word format form– Check boxes are NOT mutually exclusive– Text fields automatically expand

Q35 Do you have an estimate of drug injectors having any of the infections mentioned in the table above?

Tick ONLY ONE

Q36 For which year does the estimate apply? Which part of the country or which subgroup of drug injectors is covered by the estimate?

Year of the national estimate

Year of the partial estimate

Part of the country or subgroup of drug injectors for which the estimate applies

Estimated size of the reference population for which the estimate applies

No Proceed to Q39

Yes an estimate for the country as a whole

Yes an estimate for a part of the country or a subgroup of drug injectors

Drug-related morbidity QUANTITATIVE ESTIMATES

Boxes

Text fields

X

X

X

2002

2001

Drug injectors treated in hospitals in cities > 100,000

8,000

Empty form fields

• The ARQ does not include categories for “not known” or “no information available”

• If necessary, you should leave form fields empty

• Empty form fields will be interpreted as “no information available”

• If an estimated value equals zero, you must enter 0 or 0.0

Prevalence of drug abuse among the general population SUMMARY EXPERT OPINIONS 4

Cannabis type

Marijuana (herbal)

Hashish (resin)

Opioids

Heroin

Opium

Cocaine type

Powder (Salt)

Crack

Amphetamine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Sedatives & Tranquillisers*

Barbiturates

Benzodiazepines

Hallucinogens

LSD

Solvents & inhalants

Other drugs

Q1 Have the drugs below been used in your country in the past year?

NO YES

Q2 How are main drug classes ranked in order of prevalence?

Put in numerical order

Class of drugs Type of drugs

Q3 Within each drug class separately, how are drug types ranked in order of prevalence?


Other

Other

Other

Mark YES if any of thedrugs listed have beenused. Any source may betaken as evidence,including anecdotalreports and unique cases.

Mark only NO if you aresure that a listed drug hasnot been used at all.

Non-prescribed /non-therapeuticuse only

If you haveadded hereindividual drugtypes, youshould rankthem in Q2 asif they weredrug classes.

Rank in this column drugTYPES within each classof drugs, starting with1 for the most prevalenttype in each class,2 for the second mostprevalent type, etc.You can assign equal ranknumbers to more than onetype of drug.

Rank in this column drugCLASSES starting with1 for the most prevalentCLASS of drug,2 for the second mostprevalent class, etc.You can assign equalrank numbers to morethan one class of drugs.

Complete Q2 and Q3 only when there has beenuse of the drug in the past year (Q1 = YES).

Psychedelic “magic” mushrooms (3)

Q5 What has been the trend over the past year in prevalence of each drug type?

Q4

Large increase

Some increase

No great change

Some decrease

Large decrease

Large increase

Some increase

No great change

Some decrease

Large decrease

What has been the trend over the past year in prevalence of each drug class?

Cannabis type

Marijuana (herbal)

Hashish (resin)

Opioids

Heroin

Opium

Cocaine type

Powder (Salt)

Crack

Amphetamine type

Amphetamine

Methamphetamine

‘Ecstasy’ type


Barbiturates

Benzodiazepines

Hallucinogens

LSD


Other drugs

Class of drugs Type of drugs

Other

Other

Other

Prevalence of drug abuse among the general population SUMMARY EXPERT OPINIONS 5

If you haveadded hereindividual drugtypes, youshould indicatetheir trend inthe column fordrug classes


The trend scale points here refer to theperception in your country, not to anyspecific magnitude of change.

You should mark a scale point thatcorresponds to how in your country achange is perceived.

Trend should here be interpretedas "change in the past yearcompared to the year before".

Complete Q4 and Q5 only when there has beenuse of the drug in the past year (Q1 = YES).

Q6 Do you have an estimate of drug prevalence among the general population?

Tick ONLY ONE

Q7 For which year does the estimate apply? Which part of the country or the population is covered by the estimate?



Part of the country or sub-population for which the estimate applies

No Proceed to Q10


Yes an estimate for a part of the country or a sub-population


Prevalence of drug abuse among the general population QUANTITATIVE ESTIMATES 6

For a partial estimate you shouldalways specify the areal or populationcoverage and the (approximate) sizeof the reference population.

You canmark onlyone answer.

The year that applies to theestimate might differ from thereporting year of the ARQ orthe year in which the estimatewas published.

Cannabis type

Opioids

Heroin

Opium

Cocaine type

Powder (Salt)

Crack

Amphetamine type

Amphetamine

Methamphetamine

‘Ecstasy’ type


Barbiturates

Benzodiazepines

Hallucinogens

LSD


Other drugs

Other

Other

Other

Preferred prevalence measure

Prevalence measure used

Preferred age range

Age range used

15-64 years

Q9

All % Females %

What is the estimated prevalence rate per 100 among the general population in the REPORTING YEAR? Specify separately for the female population

All % Females %

15-64 years

Last 12 months

Q8 What is the estimated LIFETIME prevalence rate per 100 among the general population? Specify separately for the female population



If a prevalence estimate equals zero,you must also note this as 0.0.

Leaving a cell blank would beinterpreted as "no estimate available".

Preferred prevalencemeasure and agerange apply toestimates based onsurvey data.

Life-time prevalence onlyapplies to estimates basedon survey data

Complete questions Q8 and Q9 for thenational or partial estimate specified in Q7.

If the estimates are based onsurvey data, specify theprevalence measure used, ifthis was not "last 12 months"prevalence.

If the estimates are based onsurvey data, specify the agerange covered by the sampleof the survey, if this was not15-64 years.

Figures in the tableshould be rates per 100(percentages).

If you have estimatedNUMBERS you shouldconvert these first intorates per 100 of thereference population.

Prevalence of drug abuse among the school (youth) population QUANTITATIVE ESTIMATES 8

Q10 Do you have an estimate of drug prevalence among the school (youth) population?

Tick ONLY ONE

Q11 For which year does the estimate apply? Which Part of the country or sub-population is covered by the estimate?




No Proceed to Q15






The year that applies to theestimate might differ from thereporting year of the ARQ orthe year in which the estimatehas been published.

Q14

All % Females %

What is the estimated prevalence rate per 100 among the school (youth) population in the REPORTING YEAR? Specify separately for the female population

All % Females %

Last 12 months

Q13 What is the estimated LIFETIME prevalence rate per 100 among the school (youth) population? Specify separately for the female population

16 years

Q12

All % Females %

What is the estimated prevalence rate per 100 among YOUNG ADOLESCENTS population in the REPORTING YEAR? Specify separately for the female population

15-

Last 12 months

Prevalence of drug abuse among the school (youth) population QUANTITATIVE ESTIMATES 9

Cannabis type

Opioids

Heroin

Opium

Cocaine type

Powder (Salt)

Crack

Amphetamine type

Amphetamine

Methamphetamine

‘Ecstasy’ type


Barbiturates

Benzodiazepines

Hallucinogens

LSD


Other drugs

Other

Other

Other


Preferred age range

Age range used



If the estimates are basedon survey data, specifythe age range covered bythe sample of the survey,if this was not 15-16years.

Preferred prevalencemeasure and agerange apply toestimates based onsurvey data.

Complete questions Q12-Q14 for thenational or partial estimate specified in Q11.

IN Q13 and Q14 youshould always specifythe age range covered.This may be anapproximate age range.

Figures in the table should be rates per 100(percentages).

If you have estimated NUMBERS you shouldconvert these first to percentages or ratesper 100 of the reference population.

If a prevalence estimate equals zero, youmust also note this as 0.0.

Leaving a cell blank would be interpreted as"no estimate available".

If the estimates are based onsurvey data, specify theprevalence measure used, ifthis was not "last 12 months"prevalence.

Life-time prevalence only appliesto estimates based on survey data.

Any drugs (type unspecified)

Heroin

Other opioids

Cocaine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Other drugs

Q15 Has there been practice of injecting among drug users in the past year?

NO YES

Q17 Has there been practice of sharing needles or syringes among drug injectors in the past year?

No Proceed to Q19

Q18 What has been the trend over the past year in sharing needles or syringes among drug injectors?

Yes

Q16 What has been the trend in injecting over the past year?

Injecting drug abuse SUMMARY EXPERT OPINIONS 10

Large increase

Some increase

No great change

Some decrease

Large decrease

Large increase

Some increase

No great change

Some decrease

Large decrease

If you cannotanswer Q15 forindividual drugs,provide an answerfor "any drugs".

Sharing needles orsyringes means: "using aneedle or syringe that hasbeen used previously bysomeone else".

The trend scale points here refer to theperception in your country, not to anyspecific magnitude of change.

You should mark a scale point thatcorresponds to how in your country achange is perceived.


If there has been no known practice of injecting(i.e. for none of the drugs listed Q15 is answeredpositive), you can skip Q16-Q18.

Q22 What is the estimated PERCENTAGE of active drug injectors who report to have shared needles or syringes the last time they injected drugs?

Q19 Do you have an estimate of the percentage or number of drug injectors among all drug users?

Tick ONLY ONE

Q20 For which year does the estimate apply? Which part of the country or subgroup of drug users is covered by the estimate?



Part of the country or subgroup of drug users for which the estimate applies


No Proceed to Q23


Yes an estimate for a part of the country or a subgroup of drug users

Injecting drug abuse QUANTITATIVE ESTIMATES 11


Heroin

Other opioids

Cocaine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Other drugs

Q21a What is the estimated PERCENTAGE of drug injectors among all drug users?

Q21b What is the estimated NUMBER of drug injectors?



Complete questionsQ21a-Q22 for thenational or partialestimate specifiedin Q26.

If you cannotanswer Q21a-Q21bfor individual drugs,provide an answerfor "any drugs".

Presenting an estimatedpercentage of injectorsamong all drug usersimplies that you alsohave an estimate of thetotal number of activedrug users (see Q9).

If any of the estimates in Q21a-Q22 equalszero, you must also note this as 0 or 0.0.

Leaving a cell blank would be interpretedas "no estimate available".

Sharing needles orsyringes means: "using aneedle or syringe that hasbeen used previously bysomeone else".


Severe drug abuse SUMMARY EXPERT OPINIONS 12

Q23 Does your country make a distinction between drug users in general and drug users who are considered particularly problematic, chronic or in need of help?

Q24 What has been the trend over the past year in “severe / problematic” drug use?

No Proceed to Q29

Yes Large increase

Some increase

No great change

Some decrease

Large decrease

Q25 Do you have an estimate of drug users, who are considered particularly problematic, chronic users or in need of help?

Tick ONLY ONE

Q26 For which year does the estimate apply? Which part of the country or which subgroup of drug users is covered by the estimate?



Part of the country or subgroup of drug users for which the estimate applies


No Proceed to Q29


Yes an estimate for a part of the country or a subgroup of drug users

Q28 Which definition of “severe / problematic users”applies to the estimated number of Q27 and how is the estimate calculated?

Q27 What is the estimated number of “severe / problematic” drug users?

Severe drug abuse QUANTITATIVE ESTIMATES

If no strict definition can be given, specify at leastthe method of estimation. If applicable specifyalso the data sources used in the estimation.

Complete questionsQ27-Q28 for the nationalor partial estimatespecified in Q26.



The trend scale points here refer to the perception in yourcountry, not to any specific magnitude of change.You should mark a scale point that corresponds to how inyour country a change is perceived.

Trend should herebe interpreted as"change in thepast yearcompared to theyear before".


Q29 Have new drugs or new patterns of drug use been reported in the past year?

Q30 Which new drugs or new patterns of use have been reported?

New developments in prevalence and patterns of drug abuse SUMMARY EXPERT OPINIONS 13

No Proceed to Q31

Yes

Q32 Which new groups of drug users have been reported and in relation to which types of drugs?

No Proceed to Q33

Yes

Q31 Have new groups of drug users been reported in the past year?

Give a concise but explicit description


Consider as new groups of users anygroup of people defined by commonsocial, demographic, ethnic, cultural orother characteristics, including people incertain parts of the country, among whichdrug use has been observed - accordingto formal reports or expert opinions- inyour country in the past year, but not inthe year before.

Consider drugs or patterns of drug use as"new" if they have been observed -according to formal reports or expertopinions- in your country in the past year,but not in the year before.

New drugs and new patterns of use cantherefore also include drugs and patternsthat have reappeared in the country afterthey were thought to have been vanished.

New developments in prevalence and patterns of drug abuse SUMMARY EXPERT OPINIONS 14

Please use the space below to document any other developments in prevalence and patterns of drug abuse in your country over the past year.

Use the space here to add, if applicable, comments,explanations and references to the expert opinions andquantitative estimates presented in your response to theprevious questions Q1-Q32.

You may use this space also to inform UNDCP about otherrelevant developments in prevalence and patterns of drug usenot covered by the ARQ questionnaire.

Drug-related morbidity SUMMARY EXPERT OPINIONS 15

Q34 What has been the trend over the past year in prevalence of infections among drug injectors?

Large increase

Some increase

No great change

Some decrease

Large decrease

Q35 Do you have an estimate of drug injectors having any of the infections mentioned in the table above?

Tick ONLY ONE

Q36 For which year does the estimate apply? Which part of the country or which subgroup of drug injectors is covered by the estimate?



Part of the country or subgroup of drug injectors for which the estimate applies


No Proceed to Q39


Yes an estimate for a part of the country or a subgroup of drug injectors


Q33 Have there been reports about prevalence of infections among drug injectors in the past year?

NO YES

Hepatitis B

Hepatitis C

HIV

Q38 What is the estimated PERCENTAGE of infected persons among drug injectors?

Q37 What is the estimated NUMBER of infected drug injectors?

Hepatitis B

Hepatitis C

HIV

The ARQ only requiresinformation about the threelisted infections. If you wouldlike to communicate otherinfections or diseases youcan do so under AdditionalInformation at the end ofthe questionnaire.


The trend scale points here refer to the perception in your country, notto any specific magnitude of change. You should mark a scale point thatcorresponds to how in your country a change is perceived.





Q40 How are drugs ranked in order of the primary cause in drug- related deaths?



Heroin

Other opioids

Cocaine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Other drugs

Q39 Have there been reports about drug-related deaths in the past year?

NO YES

Q41 What has been the trend over the past year in drug-related deaths?

Large increase

Some increase

No great change

Some decrease

Large decrease

Drug-related mortality SUMMARY EXPERT OPINIONS 16

If you cannotanswer Q39 forindividual drugs,provide an answerfor "any drugs".

Rank in this column thedrugs listed starting with1 for the drug mostoften reported asprimary cause in drug-related deaths,2 for the drug secondmost often reported asprimary cause, etc.You can assign equalrank numbers to morethan one of the listeddrugs.

The trend scale points hererefer to the perception inyour country, not to anyspecific magnitude of change.

You should mark a scale pointthat corresponds to how inyour country a change isperceived.

Trend should herebe interpreted as"change in the pastyear compared tothe year before".

Drug-related mortality QUANTITATIVE ESTIMATES 17

Q42 Do you have an estimate of the number of drug-related deaths?

Tick ONLY ONE

Q43 For which year does the estimate apply? Which part of the country or sub-population is covered by the estimate?





No Proceed to Q48




Heroin

Other opioids

Cocaine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Other drugs

Q44 What is the estimated TOTAL number of drug-related deaths?

Q45 What is the estimated number of FATAL DRUG OVERDOSES ONLY?

Q46 What is the estimated number of drug-related AIDS DEATHS?

Q47 What is the estimated number of drug-related OTHER DEATHS (excluding fatal drug overdoses and AIDS deaths)?

If any of the estimates in Q44-Q47 equals zero,you must also note this as 0 or 0.0.

Leaving a cell blank would be interpreted as "noestimate available".

If you cannot answerQ44-Q47 for individualdrugs, provide ananswer for "any drugs".





Q49 How are drugs ranked in order of the primary cause of receiving treatment?



Cannabis type

Heroin

Other opioids

Cocaine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Other drugs

Q48 Have people received treatment for drug problems in the past year?

NO YES

Q50 What has been the trend over the past year in the numbers of people receiving treatment?

Large increase

Some increase

No great change

Some decrease

Large decrease

Q51 Do you have an estimate of the number of people receiving treatment for drug problems?

Tick ONLY ONE

Q52 For which year does the estimate apply? Which part of the country or selection of treatment facilities is covered by the estimate?



No Proceed to Q59


Yes an estimate for a part of the country or a selection of treatment facilities

Drug treatment SUMMARY EXPERT OPINIONS 18

Part of the country for which the estimate applies

Types of treatment facilities included and/or excluded in the estimate

Drug treatment QUANTITATIVE ESTIMATES

If you cannotanswer Q48-Q50for individualdrugs, provide ananswer for "anydrugs".

The trend scale points hererefer to the perception inyour country, not to anyspecific magnitude of change.

You should mark a scale pointthat corresponds to how inyour country a change isperceived.

Rank in this column thedrugs listed starting with1 for the drug mostoften reported asprimary cause ofreceiving treatment,2 for the drug secondmost often reported asprimary cause, etc.You can assign equalrank numbers to morethan one of the listeddrugs.


For a partial estimate you should always specifythe areal coverage.If treatment in your country is restricted to specificgroups of the population, for example nationalsubjects only, you should also specify excludedgroups.

Specify concise but explicit by typesof general and specialised treatmentfacilities.


Trend should herebe interpreted as"change in the pastyear compared tothe year before".

If estimates for ‘all drugs’ in Q53-Q57 above include also treatment for alcohol problems, please tick here

Q58

All people receiving treatment during the year

People STARTING treatment during the year

People in treatment at CENSUS DATE in the year

People discharged from treatment during the year

Other

Tick as Appropriate

Tick as Appropriate

Tick as Appropriate

Tick as Appropriate

Tick as Appropriate

Which definition of ‘people treated for drug problems’applies to the figures in the columns of Q53 -Q57 above?

Q53 Q54 Q55 Q56 Q57


Cannabis type

Heroin

Other opioids

Cocaine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Other drugs

Q53 What is the estimated NUMBER of people receiving treatment for drug problems?

Q54 What is the estimated PERCENTAGE of people receiving treatment for the FIRST TIME EVER among people in treatment?

Q55 What is the estimated PERCENTAGE of FEMALES among people in treatment

Q56 What is the estimated MEAN AGE of people in treatment?

Q57 What is the estimated PERCENTAGE of DRUG INJECTORS among people in treatment?

Drug treatment QUANTITATIVE ESTIMATES 19

This is only relevant if you have provided inQ53-Q57 estimates relating to "any drugs"

Give a concisebut explicitdescription

You can only mark one answer in each column

The applicable definitionshould be marked inreference to each columnof estimates of Q53-Q57.

If you cannotanswer Q53-57for individualdrugs, providean answer for"any drugs".

Complete questions Q53-Q57 for the nationalor partial estimate specified in Q52.

If any of the estimates in Q53-Q57 equals zero, you mustalso note this as 0 or 0.0.

Leaving a cell blank would be interpreted as "no estimateavailable".

Data collection capacity 20

Q60

Poor Moderate Good

How would you qualify the present suitability of these instruments for making national estimates about the drug situation?

Q59 Has your country capacity with regard to data collection instruments specified below?

Q61 If applicable, what are the main obstacles for implementation or improvement of data collection instruments suitable for making national estimates about the drug situation?

Registers

Specialised treatment register

Registers on drug-related morbidity

Registers on drug-related mortality

Survey instruments

Prevalence surveys among the general population

Prevalence surveys among school populations

Surveys among drug users

Qualitative research instruments

Rapid Situation Assessment

Other

NO YES

Give a concisebut explicitdescription


Capacity should be interpreted as"existing/available" in the caseof registers, and "being able toimplement" in the case of surveyand other research instruments

Complete question Q60 only ifthe capacity in your countryexists (Q59 = YES).

Please list below relevant national reports or major studies about the extent, patterns or trends in drug abuse in your country, published in the past year. Specify author, title and year of publication. Attach copies of documents and reports if possible.

Reports 21

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

You should at least include here references to the publicationsthat provide details of the quantitative estimates provided in thepreceding sections of the ARQ.

You are kindly requested to attach, if possible, (electronic)copies of the listed reports to the submitted and completedquestionnaire, in particular when these reports have not (yet)been published.

If a report is available on the Web you may also refer to theappropriate Web address.

Please use the space below to add notes of clarification to any of the information contained in this questionnaire or to document any issue that you wish to draw to the attention of UNDCP.

Additional information 22

Specify here :

* answers to previous questions that could not fit in the corresponding form fields;

* relevant information that is not consistent with the figures reported in the indicator tables.;

* any information about the drug situation of your country that is not covered by the ARQ.

Automatic expansion of text fields(Word Form)

For which year does the estimate apply? Which part of the country or which subgroup of drug injectors is covered by the estimate?

1998

200000

Various types of RSAs can be conducted, following a continuum from brief initial assessments at an early stage of intervention development through to more focussed assessments designed to develop specific projects. An RSA can be broad-based, as was the case with many of the UNDCP-contracted country studies. These studies described trends and patterns of drug abuse in a few important settings in the given countries, the characteristics of the drug-abusing population, their needs, availability of drug treatment services for the drug-abusing population, existing policy responses or other community-based interventions that had taken place, what new interventions were urgently needed and so on. RSAs can also however be more focussed on particular aspects of drug abuse such as the design of communication strategies and messages, drug-injecting and risks and prevalence of the human immunodeficiency virus (HIV) among injecting drug users. RSAs can be conducted once or may be repeated over time.


Q35 Q36 Do you have an estimate of drug injectors having any of the infections mentioned in the table above?

T ick O N LY O N E

No Proceed to Q39

Yes Year of the national estim ate an estim ate fo r the coun try as a w ho le

Yes an estim ate fo r a part o f the coun try o r a subgroup o f d rug in jec to rs

Year of the partial estim ate

Part of the country or subgroup of drug injectors for which the estim ate applies

Estim ated s ize o f the re ference popula tion for w h ich the estim ate app lies

Please use the space below to add notes of clarification to any of the information contained in this questionnaire or to document any issue that you wish to draw to the attention of UNDCP.

Additional information 22

(3) Psychedelic “magic” mushrooms

Cannabis type

Opioids

Heroin

Opium

Cocaine type

Powder (Salt)

Crack

Amphetamine type

Amphetamine

Methamphetamine

‘Ecstasy’ type


Barbiturates

Benzodiazepines

Hallucinogens

LSD


Other drugs

Other

Other

Other



Preferred age range

Age range used

15-64 years

Q9

All % Females %

What is the estimated prevalence rate per 100 among the general population in the REPORTING YEAR? Specify separately for the female population

All % Females %

15-64 years

Last 12 months

Q8 What is the estimated LIFETIME prevalence rate per 100 among the general population? Specify separately for the female population


If estimates for ‘all drugs’ in Q53-Q57 above include also treatment for alcohol problems, please tick here

Q58

All people receiving treatment during the year

People STARTING treatment during the year

People in treatment at CENSUS DATE in the year

People discharged from treatment during the year

Other

Tick as Appropriate

Tick as Appropriate

Tick as Appropriate

Tick as Appropriate

Tick as Appropriate

Which definition of ‘people treated for drug problems’applies to the figures in the columns of Q53 -Q57 above?

Q53 Q54 Q55 Q56 Q57


Cannabis type

Heroin

Other opioids

Cocaine type

Amphetamine

Methamphetamine

‘Ecstasy’ type

Other drugs

Q53 What is the estimated NUMBER of people receiving treatment for drug problems?

Q54 What is the estimated PERCENTAGE of people receiving treatment for the FIRST TIME EVER among people in treatment?

Q55 What is the estimated PERCENTAGE of FEMALES among people in treatment

Q56 What is the estimated MEAN AGE of people in treatment?

Q57 What is the estimated PERCENTAGE of DRUG INJECTORS among people in treatment?

Drug treatment QUANTITATIVE ESTIMATES 19

arq part ii data management

Documents